Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYP-OP-RT: Hypofractionated vs Standard Post-Operative Salvage Radiotherapy in Prostate Cancer
NCT07483658Recruiting
- Sponsor
- CHU de Québec-Université Laval
- Start
- May 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Randomised, open-label trial in prostate cancer (PCa) (2 arms), sponsored by CHU de Québec-Université Laval. Primary endpoint: Incidence of Grade 2 or Higher Genitourinary (GU) or Gastrointestinal (GI) Toxicity at 24 months. Started May 2026; status: recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07483658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07483658.